NEWS ROOM

BIND Biosciences, Inc. named as one of the "Fierce 15" leading biotech companies of 2008

06/24/2008

CAMBRIDGE, MA – June 24, 2008 – BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing an entirely new class of targeted therapeutics based on multifunctional nanoparticles, announced today that they were selected by FierceBiotech for its annual “Fierce 15” list, designating it as one of the top biotechnology companies of 2008.  FierceBiotech evaluated hundreds of privately held firms based on a variety of factors including company vision, strength of technology, partnerships and competitive market position.  A complete list of “Fierce 15” companies is available online at www.fiercebiotech.com.

About BIND Biosciences, Inc.
BIND Biosciences is a biopharmaceutical company focused on developing “smart” therapeutic targeted nanoparticles capable of differential delivery and controlled drug release to diseased tissue.  The company’s technology enables highly selective targeting at the cellular level and is capable of delivering bioactive agents ranging from approved drugs to emerging drug modalities.  The company’s product platform is broadly applicable across the therapeutic areas of oncology, inflammatory disease, cardiovascular disease and infectious disease.  Their initial product development efforts are focused on cancer and cardiovascular disease with their first product anticipated to enter the clinic in 2009.

BIND was founded in 2006 by two pioneers in the field of therapeutic targeted nanoparticles, Dr. Robert Langer, MIT Institute Professor, and Dr. Omid Farokhzad, Harvard Medical School Assistant Professor.  The company licensed a large patent estate on a worldwide exclusive basis from MIT and Brigham and Women’s Hospital – Harvard Medical School covering the scientific founders’ work in targeted nanoparticle therapeutics.  The company has assembled a world-class management and scientific team drawn from companies such as Millennium Pharmaceuticals, Alkermes, Infinity Pharmaceuticals, Momenta, Acceleron Pharma, Boehringer Ingelheim Pharmaceuticals and Sepracor. BIND is backed by leading venture capital firms, Polaris Venture Partners, Flagship Ventures, ARCH Ventures and NanoDimension.  For more information, please visit the company’s web site at www.bindbio.com.

Contacts
BIND Biosciences, Inc.
Glenn Batchelder, President and CEO
617-491-3400